marjac,I know this does not need to be said, but be prepared for a lot of rule 60 questions on Feb. 11. It does not seem to me that this shareholder lawsuit is so unique as to require a rule 24 hearing. After all shareholders have long been recognized as plaintiffs in many cases. I’m hoping we get a good panel that is more interested in the basis of our suit— fraud upon the court.
My guess would see 6 SP within a few days and lead to a climb over the next 6 to 12 months -to 10 and maybe 15 in two years - all the current generic sales would revert back to Amarin so that would give lift
I think the company has been damaged by du but also other factors - covid - lack of take up - hesitation impact over new markets - poor management - greedy management
But nonetheless the downside is limited the upside slow but significant over time
The buzz rise / takeover speculation that the stock achieved post reduce it is now harder to replicate
The right panel : a panel that has read the case : a panel that sees the fact that the patents could not be rendered obvious when K snd Mori are removed (as they most surely must be ): a panel that wants to see Justice and fairness in the USA patent system
And Marjac leading them through to our promised land -
Market Data 
Markets 
AI
